Share page on LinkedIn

Diversity and inclusion in clinical trials

Paving the way for diversity and inclusion in clinical trials: establishing a platform for improvement

Beyond buzzwords: DE&I in rare disease

Beyond buzzwords: DE&I in rare disease

In an interdisciplinary panel discussion of research leaders and community advocates, we led a conversation on key challenges in advancing diversity, equity and inclusion and equitable access to rare disease clinical trials.

View panel discussion
Diversity and inclusion in clinical trials whitepaper

Diversity and inclusion in clinical trials whitepaper

Examining how the field of clinical research currently approaches diversity and inclusion gives us a baseline understanding on which we can build and make the necessary changes for improvement in the future. ICON looked at the barriers to accessing under-represented subgroups, the regulatory landscape and how organisations are addressing this issue and brings together the findings in this Whitepaper.

Read the whitepaper
Biopharma perspective: The promise of decentralised models and diversity in clinical trials

The promise of decentralised models and diversity in clinical trials

ICON invited senior executives from Amgen, Sanofi, Eli Lilly and Janssen Research & Development LLC to discuss how decentralised and hybrid clinical trial models can provide increased resilience and how their respective organisations are currently (or likely) to address diversity and inclusion in clinical trials into the future.

Read the whitepaper
Clinical trial diversity in a post-pandemic world

Clinical trial diversity in a post-pandemic world

Clinical trial diversity has been a major topic of discussion for years, but it took the COVID-19 pandemic for the biopharma industry to fully realise the importance of recruiting diverse populations into studies.

Watch the webinar

Diversity and inclusion blogs and media contributions